ErVimmune

ErVimmune (previously ErVaccine Technologies) develops cancer vaccines and T cell-based immunotherapies targeting new tumor antigens to address a high medical need in cold tumors.

Our approach is based on innovative bioinformatics algorithms to identify potential epitopes that are validated by proteomics and immunology assays: from bioinformatics to proteomics.

The first candidates are represented by virus-like antigens derived from Human Endogenous Retroviruses (HERVs). We are dedicated to discovering more accurate tumor epitopes that are shared between patients.

Our initial target indication is triple negative breast cancer (TNBC), and we have already realized promising preclinical results that demonstrate the ability of HERV-specific T-cells to recognize and eliminate TNBC cells.